Serum resistin in older patients with hip fracture: Relationship with comorbidity and biochemical determinants of bone metabolism

Cytokine

Volumn 56, Issue 2, 2011, Pages 157-166

  Fisher, A ^a,b   Southcott, E ^a   Li, R ^a   Srikusalanukul, W ^a,b   Davis, M ^a,b   Smith, P ^a,b  

^a CANBERRA HOSPITAL   (Australia)

^b The Australian National University   (Australia)

Author keywords

Bone metabolism; Diabetes; Hip fracture; Resistin; Stroke

Indexed keywords

ADIPONECTIN; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; MAGNESIUM; OSTEOCALCIN; RESISTIN;

AGED; ARTICLE; BONE METABOLISM; BONE TURNOVER; CERVICAL SPINE FRACTURE; COMORBIDITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATOLOGICAL PARAMETERS; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; BONE AND BONES; FEMALE; HIP FRACTURES; HUMANS; MALE; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RESISTIN;

EID: 80053333613     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.06.023     Document Type: Article

References (131)

1. Steppan C.M., Bailey S.T., Bhat S., Brown E.J., Banerjee R.R., Wright C.M., et al. The hormone resistin links obesity to diabetes. Nature 2001, 409:307-312.
2. Rajala M.W., Lin Y., Ranalletta M., Yang X.M., Qian H., Gingerich R., et al. Cell type-specific expression and coregulation of murine resistin and resistin-like molecule-alpha in adipose tissue. Mol Endocrinol 2002, 16:1920-1930.
3. Steppan C.M., Lazar M.A. The current biology of resistin. J Intern Med 2004, 255:439-447.
4. Dai M.H., Xia T., Chen X.D., Gan L., Feng S.Q., Qiu H., et al. Cloning and characterization of porcine resistin gene. Domest Anim Endocrinol 2006, 30:88-97.
5. Patel S.D., Rajala M.W., Rossetti L., Scherer P.E., Shapiro L. Disulfide-dependent multimeric assembly of resistin family hormones. Science 2004, 304:1154-1158.
6. Gerber M., Boettner A., Seidel B., Lammert A., Bar J., Schuster E., et al. Serum resistin levels of obese and lean children and adolescents: biochemical analysis and clinical relevance. J Clin Endocrinol Metab 2005, 90:4503-4509.
7. Graveleau C., Zaha V.G., Mohajer A., Banerjee R.R., Dudley-Rucker N., Steppan C.M., et al. Mouse and human resistins impair glucose transport in primary mouse cardiomyocytes, and oligomerization is required for this biological action. J Biol Chem 2005, 280:31679-31685.
8. Jorgensen S.B., Honeyman J., Oakhill J.S., Fazakerley D., Stockli J., Kemp B.E., et al. Oligomeric resistin impairs insulin and AICAR-stimulated glucose uptake in mouse skeletal muscle by inhibiting GLUT4 translocation. Am J Physiol Endocrinol Metab 2009, 297:E57-E66.
9. McTernan P.G., Kusminski C.M., Kumar S. Resistin. Curr Opin Lipidol 2006, 17:170-175.
10. Galic S., Oakhill J.S., Steinberg G.R. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2010, 316:129-139.
11. Patel L., Buckels A.C., Kinghorn I.J., Murdock P.R., Holbrook J.D., Plumpton C., et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003, 300:472-476.
12. Yang R.Z., Huang Q., Xu A., McLenithan J.C., Eisen J.A., Shuldiner A.R., et al. Comparative studies of resistin expression and phylogenomics in human and mouse. Biochem Biophys Res Commun 2003, 310:927-935.
13. Thommesen L., Stunes A.K., Monjo M., Grosvik K., Tamburstuen M.V., Kjobli E., et al. Expression and regulation of resistin in osteoblasts and osteoclasts indicate a role in bone metabolism. J Cell Biochem 2006, 99:824-834.
14. Menzaghi C., Coco A., Salvemini L., Thompson R., De Cosmo S., Doria A., et al. Heritability of serum resistin and its genetic correlation with insulin resistance-related features in nondiabetic Caucasians. J Clin Endocrinol Metab 2006, 91:2792-2795.
15. Pantsulaia I., Livshits G., Trofimov S., Kobyliansky E. Genetic and environmental determinants of circulating resistin level in a community-based sample. Eur J Endocrinol 2007, 156:129-135.
16. Hivert M.F., Manning A.K., McAteer J.B., Dupuis J., Fox C.S., Cupples L.A., et al. Association of variants in RETN with plasma resistin levels and diabetes-related traits in the Framingham Offspring Study. Diabetes 2009, 58:750-756.
17. Asano H., Izawa H., Nagata K., Nakatochi M., Kobayashi M., Hirashiki A., et al. Plasma resistin concentration determined by common variants in the resistin gene and associated with metabolic traits in an aged Japanese population. Diabetologia 2010, 53:234-246.
18. Menzaghi C., Trischitta V. Genetics of serum resistin: a paradigm of population-specific regulation?. Diabetologia 2010, 53:226-228.
19. Banerjee R.R., Rangwala S.M., Shapiro J.S., Rich A.S., Rhoades B., Qi Y., et al. Regulation of fasted blood glucose by resistin. Science 2004, 303:1195-1198.
20. Milan G., Granzotto M., Scarda A., Calcagno A., Pagano C., Federspil G., et al. Resistin and adiponectin expression in visceral fat of obese rats: effect of weight loss. Obes Res 2002, 10:1095-1103.
21. Muse E.D., Obici S., Bhanot S., Monia B.P., McKay R.A., Rajala M.W., et al. Role of resistin in diet-induced hepatic insulin resistance. J Clin Invest 2004, 114:232-239.
22. Rangwala S.M., Rich A.S., Rhoades B., Shapiro J.S., Obici S., Rossetti L., et al. Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes 2004, 53:1937-1941.
23. Luo Z., Zhang Y., Li F., He J., Ding H., Yan L., et al. Resistin induces insulin resistance by both AMPK-dependent and AMPK-independent mechanisms in HepG2 cells. Endocrine 2009, 36:60-69.
24. Lee J.H., Bullen J.W., Stoyneva V.L., Mantzoros C.S. Circulating resistin in lean, obese, and insulin-resistant mouse models: lack of association with insulinemia and glycemia. Am J Physiol Endocrinol Metab 2005, 288:E625-E632.
25. Way J.M., Gorgun C.Z., Tong Q., Uysal K.T., Brown K.K., Harrington W.W., et al. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 2001, 276:25651-25653.
26. Maebuchi M., Machidori M., Urade R., Ogawa T., Moriyama T. Low resistin levels in adipose tissues and serum in high-fat fed mice and genetically obese mice: development of an ELISA system for quantification of resistin. Arch Biochem Biophys 2003, 416:164-170.
27. Utzschneider K.M., Carr D.B., Tong J., Wallace T.M., Hull R.L., Zraika S., et al. Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia 2005, 48:2330-2333.
28. Nagaev I., Bokarewa M., Tarkowski A., Smith U. Human resistin is a systemic immune-derived proinflammatory cytokine targeting both leukocytes and adipocytes. PLoS One 2006, 1:e31.
29. Tilg H., Moschen A.R. Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci (Lond) 2008, 114:275-288.
30. Qasim A.N., Metkus T.S., Tadesse M., Lehrke M., Restine S., Wolfe M.L., et al. Resistin gene variation is associated with systemic inflammation but not plasma adipokine levels, metabolic syndrome or coronary atherosclerosis in nondiabetic Caucasians. Clin Endocrinol (Oxf) 2009, 70:698-705.
31. Degawa-Yamauchi M., Bovenkerk J.E., Juliar B.E., Watson W., Kerr K., Jones R., et al. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003, 88:5452-5455.
32. Heilbronn L.K., Rood J., Janderova L., Albu J.B., Kelley D.E., Ravussin E., et al. Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J Clin Endocrinol Metab 2004, 89:1844-1848.
33. Pagano C., Soardo G., Pilon C., Milocco C., Basan L., Milan G., et al. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab 2006, 91:1081-1086.
34. Zhang H., Xie H., Zhao Q., Xie G.Q., Wu X.P., Liao E.Y., et al. Relationships between serum adiponectin, apelin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in post-menopausal Chinese women. J Endocrinol Invest 2010, 33:707-711.
35. Vozarova de Courten B., Degawa-Yamauchi M., Considine R.V., Tataranni P.A. High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indians. Diabetes 2004, 53:1279-1284.
36. Reilly M.P., Lehrke M., Wolfe M.L., Rohatgi A., Lazar M.A., Rader D.J. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005, 111:932-939.
37. Qatanani M., Szwergold N.R., Greaves D.R., Ahima R.S., Lazar M.A. Macrophage-derived human resistin exacerbates adipose tissue inflammation and insulin resistance in mice. J Clin Invest 2009.
38. McTernan P.G., Fisher F.M., Valsamakis G., Chetty R., Harte A., McTernan C.L., et al. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab 2003, 88:6098-6106.
39. Norata G.D., Ongari M., Garlaschelli K., Raselli S., Grigore L., Catapano A.L. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol 2007, 156:279-284.
40. Osawa H., Ochi M., Tabara Y., Kato K., Yamauchi J., Takata Y., et al. Serum resistin is positively correlated with the accumulation of metabolic syndrome factors in type 2 diabetes. Clin Endocrinol (Oxf) 2008, 69:74-80.
41. Chen B.H., Song Y., Ding E.L., Manson J.E., Roberts C.K., Rifai N., et al. Association of resistin promoter polymorphisms with plasma resistin levels and type 2 diabetes in women and men. Int J Mol Epidemiol Genet 2010, 1:167-174.
42. Gharibeh M.Y., Al Tawallbeh G.M., Abboud M.M., Radaideh A., Alhader A.A., Khabour O.F. Correlation of plasma resistin with obesity and insulin resistance in type 2 diabetic patients. Diabetes Metab 2010, 36:443-449.
43. Pischon T., Bamberger C.M., Kratzsch J., Zyriax B.C., Algenstaedt P., Boeing H., et al. Association of plasma resistin levels with coronary heart disease in women. Obes Res 2005, 13:1764-1771.
44. Frankel D.S., Vasan R.S., D'Agostino R.B., Benjamin E.J., Levy D., Wang T.J., et al. Resistin, adiponectin, and risk of heart failure the Framingham offspring study. J Am Coll Cardiol 2009, 53:754-762.
45. Pilz S., Weihrauch G., Seelhorst U., Wellnitz B., Winkelmann B.R., Boehm B.O., et al. Implications of resistin plasma levels in subjects undergoing coronary angiography. Clin Endocrinol (Oxf) 2007, 66:380-386.
46. Weikert C., Westphal S., Berger K., Dierkes J., Mohlig M., Spranger J., et al. Plasma resistin levels and risk of myocardial infarction and ischemic stroke. J Clin Endocrinol Metab 2008, 93:2647-2653.
47. Axelsson J., Bergsten A., Qureshi A.R., Heimburger O., Barany P., Lonnqvist F., et al. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int 2006, 69:596-604.
48. Ellington A.A., Malik A.R., Klee G.G., Turner S.T., Rule A.D., Mosley T.H., et al. Association of plasma resistin with glomerular filtration rate and albuminuria in hypertensive adults. Hypertension 2007, 50:708-714.
49. Malyszko J., Malyszko J.S., Kozminski P., Pawlak K., Mysliwiec M. Elevated resistin is related to inflammation and residual renal function in haemodialysed patients. Nephrology (Carlton) 2007, 12:246-253.
50. Marra F., Bertolani C. Adipokines in liver diseases. Hepatology 2009, 50:957-969.
51. Lehrke M., Reilly M.P., Millington S.C., Iqbal N., Rader D.J., Lazar M.A. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 2004, 1:e45.
52. Kunnari A., Ukkola O., Paivansalo M., Kesaniemi Y.A. High plasma resistin level is associated with enhanced highly sensitive C-reactive protein and leukocytes. J Clin Endocrinol Metab 2006, 91:2755-2760.
53. Migita K., Maeda Y., Miyashita T., Kimura H., Nakamura M., Ishibashi H., et al. The serum levels of resistin in rheumatoid arthritis patients. Clin Exp Rheumatol 2006, 24:698-701.
54. Karmiris K., Koutroubakis I.E., Kouroumalis E.A. Leptin, adiponectin, resistin, and ghrelin - Implications for inflammatory bowel disease. Mol Nutr Food Res 2008, 52:855-866.
55. Koch A., Gressner O.A., Sanson E., Tacke F., Trautwein C. Serum resistin levels in critically ill patients are associated with inflammation, organ dysfunction and metabolism and may predict survival of non-septic patients. Crit Care 2009, 13:R95.
56. Oh K.W., Lee W.Y., Rhee E.J., Baek K.H., Yoon K.H., Kang M.I., et al. The relationship between serum resistin, leptin, adiponectin, ghrelin levels and bone mineral density in middle-aged men. Clin Endocrinol (Oxf) 2005, 63:131-138.
57. Almehed K., D'Elia H.F., Bokarewa M., Carlsten H. Role of resistin as a marker of inflammation in systemic lupus erythematosus. Arthritis Res Ther 2008, 10:R15.
58. Peng X.D., Xie H., Zhao Q., Wu X.P., Sun Z.Q., Liao E.Y. Relationships between serum adiponectin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in Chinese men. Clin Chim Acta 2008, 387:31-35.
59. Forsblad d'Elia H., Pullerits R., Carlsten H., Bokarewa M. Resistin in serum is associated with higher levels of IL-1Ra in post-menopausal women with rheumatoid arthritis. Rheumatology (Oxford) 2008, 47:1082-1087.
60. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470.
61. Efstathiou S.P., Tsiakou A.G., Tsioulos D.I., Panagiotou T.N., Pefanis A.V., Achimastos A.D., et al. Prognostic significance of plasma resistin levels in patients with atherothrombotic ischemic stroke. Clin Chim Acta 2007, 378:78-85.
62. Lubos E., Messow C.M., Schnabel R., Rupprecht H.J., Espinola-Klein C., Bickel C., et al. Resistin, acute coronary syndrome and prognosis results from the AtheroGene study. Atherosclerosis 2007, 193:121-128.
63. Momiyama Y., Ohmori R., Uto-Kondo H., Tanaka N., Kato R., Taniguchi H., et al. Serum resistin levels and cardiovascular events in patients undergoing percutaneous coronary intervention. J Atheroscler Thromb 2010.
64. Youn B.S., Yu K.Y., Park H.J., Lee N.S., Min S.S., Youn M.Y., et al. Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. J Clin Endocrinol Metab 2004, 89:150-156.
65. Chen B.H., Song Y., Ding E.L., Roberts C.K., Manson J.E., Rifai N., et al. Circulating levels of resistin and risk of type 2 diabetes in men and women: results from two prospective cohorts. Diabetes Care 2009, 32:329-334.
66. Takata Y., Osawa H., Kurata M., Kurokawa M., Yamauchi J., Ochi M., et al. Hyperresistinemia is associated with coexistence of hypertension and type 2 diabetes. Hypertension 2008, 51:534-539.
67. Tsukahara T., Nakashima E., Watarai A., Hamada Y., Naruse K., Kamiya H., et al. Polymorphism in resistin promoter region at -420 determines the serum resistin levels and may be a risk marker of stroke in Japanese type 2 diabetic patients. Diabetes Res Clin Pract 2009, 84:179-186.
68. Vilarrasa N., Vendrell J., Maravall J., Broch M., Estepa A., Megia A., et al. Distribution and determinants of adiponectin, resistin and ghrelin in a randomly selected healthy population. Clin Endocrinol (Oxf) 2005, 63:329-335.
69. Al-Daghri N.M., Al-Attas O.S., Hussain T., Sabico S., Bamakhramah A. Altered levels of adipocytokines in type 2 diabetic cigarette smokers. Diabetes Res Clin Pract 2009, 83:e37-e39.
70. Burnett M.S., Devaney J.M., Adenika R.J., Lindsay R., Howard B.V. Cross-sectional associations of resistin, coronary heart disease, and insulin resistance. J Clin Endocrinol Metab 2006, 91:64-68.
71. Yaturu S., Daberry R.P., Rains J., Jain S. Resistin and adiponectin levels in subjects with coronary artery disease and type 2 diabetes. Cytokine 2006, 34:219-223.
72. Mojiminiyi O.A., Abdella N.A. Associations of resistin with inflammation and insulin resistance in patients with type 2 diabetes mellitus. Scand J Clin Lab Invest 2007, 67:215-225.
73. Lim S., Koo B.K., Cho S.W., Kihara S., Funahashi T., Cho Y.M., et al. Association of adiponectin and resistin with cardiovascular events in Korean patients with type 2 diabetes: the Korean atherosclerosis study (KAS): a 42-month prospective study. Atherosclerosis 2008, 196:398-404.
74. Osawa H., Doi Y., Makino H., Ninomiya T., Yonemoto K., Kawamura R., et al. Diabetes and hypertension markedly increased the risk of ischemic stroke associated with high serum resistin concentration in a general Japanese population: the Hisayama Study. Cardiovasc Diabetol 2009, 8:60.
75. Piestrzeniewicz K., Luczak K., Komorowski J., Maciejewski M., Jankiewicz Wika J., Goch J.H. Resistin increases with obesity and atherosclerotic risk factors in patients with myocardial infarction. Metabolism 2008, 57:488-493.
76. Thomopoulos C., Daskalaki M., Papazachou O., Rodolakis N., Bratsas A., Papadopoulos D.P., et al. Association of resistin and adiponectin with different clinical blood pressure phenotypes. J Hum Hypertens 2011, 25:38-46.
77. Ohmori R., Momiyama Y., Kato R., Taniguchi H., Ogura M., Ayaori M., et al. Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. J Am Coll Cardiol 2005, 46:379-380.
78. Lee J.H., Chan J.L., Yiannakouris N., Kontogianni M., Estrada E., Seip R., et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 2003, 88:4848-4856.
79. Mautalen C.A., Vega E.M., Einhorn T.A. Are the etiologies of cervical and trochanteric hip fractures different?. Bone 1996, 18:133S-137S.
80. Fox K.M., Magaziner J., Hebel J.R., Kenzora J.E., Kashner T.M. Intertrochanteric versus femoral neck hip fractures: differential characteristics, treatment, and sequelae. J Gerontol A Biol Sci Med Sci 1999, 54:M635-M640.
81. Stewart A., Porter R.W., Primrose W.R., Walker L.G., Reid D.M. Cervical and trochanteric hip fractures: bone mass and other parameters. Clin Rheumatol 1999, 18:201-206.
82. Pulkkinen P., Eckstein F., Lochmuller E.M., Kuhn V., Jamsa T. Association of geometric factors and failure load level with the distribution of cervical vs trochanteric hip fractures. J Bone Miner Res 2006, 21:895-901.
83. Haentjens P., Autier P., Barette M., Venken K., Vanderschueren D., Boonen S. Survival and functional outcome according to hip fracture type: a one-year prospective cohort study in elderly women with an intertrochanteric or femoral neck fracture. Bone 2007, 41:958-964.
84. Kaptoge S., Beck T.J., Reeve J., Stone K.L., Hillier T.A., Cauley J.A., et al. Prediction of incident hip fracture risk by femur geometry variables measured by hip structural analysis in the study of osteoporotic fractures. J Bone Miner Res 2008, 23:1892-1904.
85. Lee J.H., Ort T., Ma K., Picha K., Carton J., Marsters P.A., et al. Resistin is elevated following traumatic joint injury and causes matrix degradation and release of inflammatory cytokines from articular cartilage in vitro. Osteoarthritis Cartilage 2009, 17:613-620.
86. Fisher A., Srikusalanukul W., Davis M., Smith P. Hip fracture type: important role of parathyroid hormone (PTH) response to hypovitaminosis D. Bone 2010, 47:400-407.
87. Vergnaud P., Garnero P., Meunier P.J., Breart G., Kamihagi K., Delmas P.D. Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. J Clin Endocrinol Metab 1997, 82:719-724.
88. Horiuchi T., Kazama H., Araki A., Inoue J., Hosoi T., Onouchi T., et al. Impaired gamma carboxylation of osteocalcin in elderly women with type II diabetes mellitus: relationship between increase in undercarboxylated osteocalcin levels and low bone mineral density. J Bone Miner Metab 2004, 22:236-240.
89. Garnero P. Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring. Mol Diagn Ther 2008, 12:157-170.
90. Eastell R., Hannon R.A. Biomarkers of bone health and osteoporosis risk. Proc Nutr Soc 2008, 67:157-162.
91. Tanaka S., Narusawa K., Onishi H., Miura M., Hijioka A., Kanazawa Y., et al. Lower osteocalcin and osteopontin contents of the femoral head in hip fracture patients than osteoarthritis patients. Osteoporos Int 2010, 22:587-597.
92. Zhou Y., Li Y., Zhang D., Wang J., Yang H. Prevalence and predictors of osteopenia and osteoporosis in postmenopausal Chinese women with type 2 diabetes. Diabetes Res Clin Pract 2010, 90:261-269.
93. Ivaska K.K., Gerdhem P., Vaananen H.K., Akesson K., Obrant K.J. Bone turnover markers and prediction of fracture: a prospective follow-up study of 1040 elderly women for a mean of 9years. J Bone Miner Res 2010, 25:393-403.
94. Yaturu S., Reddy R.D., Rains J., Jain S.K. Plasma and urine levels of resistin and adiponectin in chronic kidney disease. Cytokine 2007, 37:1-5.
95. Lee N.K., Sowa H., Hinoi E., Ferron M., Ahn J.D., Confavreux C., et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007, 130:456-469.
96. Ferron M., Wei J., Yoshizawa T., Del Fattore A., DePinho R.A., Teti A., et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 2010, 142:296-308.
97. Fulzele K., Riddle R.C., DiGirolamo D.J., Cao X., Wan C., Chen D., et al. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell 2010, 142:309-319.
98. Lee N.K., Karsenty G. Reciprocal regulation of bone and energy metabolism. Trends Endocrinol Metab 2008, 19:161-166.
99. Confavreux C.B., Levine R.L., Karsenty G. A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms. Mol Cell Endocrinol 2009, 310:21-29.
100. Motyl K.J., McCabe L.R., Schwartz A.V. Bone and glucose metabolism: a two-way street. Arch Biochem Biophys 2010, 503:2-10.
101. Kindblom J.M., Ohlsson C., Ljunggren O., Karlsson M.K., Tivesten A., Smith U., et al. Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. J Bone Miner Res 2009, 24:785-791.
102. Bao Y.Q., Zhou M., Zhou J., Lu W., Gao Y.C., Pan X.P., et al. Relationship between serum osteocalcin and glycaemic variability in Type 2 diabetes. Clin Exp Pharmacol Physiol 2010, 38:50-54.
103. Im J.A., Yu B.P., Jeon J.Y., Kim S.H. Relationship between osteocalcin and glucose metabolism in postmenopausal women. Clin Chim Acta 2008, 396:66-69.
104. Fernandez-Real J.M., Izquierdo M., Ortega F., Gorostiaga E., Gomez-Ambrosi J., Moreno-Navarrete J.M., et al. The relationship of serum osteocalcin concentration to insulin secretion, sensitivity, and disposal with hypocaloric diet and resistance training. J Clin Endocrinol Metab 2009, 94:237-245.
105. Zhou M., Ma X., Li H., Pan X., Tang J., Gao Y., et al. Serum osteocalcin concentrations in relation to glucose and lipid metabolism in Chinese individuals. Eur J Endocrinol 2009, 161:723-729.
106. Hwang Y.C., Jeong I.K., Ahn K.J., Chung H.Y. The uncarboxylated form of osteocalcin is associated with improved glucose tolerance and enhanced beta-cell function in middle-aged male subjects. Diabetes Metab Res Rev 2009, 25:768-772.
107. Pittas A.G., Harris S.S., Eliades M., Stark P., Dawson-Hughes B. Association between serum osteocalcin and markers of metabolic phenotype. J Clin Endocrinol Metab 2009, 94:827-832.
108. Yeap B.B., Chubb S.A., Flicker L., McCaul K.A., Ebeling P.R., Beilby J.P., et al. Reduced serum total osteocalcin is associated with metabolic syndrome in older men via waist circumference, hyperglycemia, and triglyceride levels. Eur J Endocrinol 2010, 163:265-272.
109. Verhaeghe J., Suiker A.M., Nyomba B.L., Visser W.J., Einhorn T.A., Dequeker J., et al. Bone mineral homeostasis in spontaneously diabetic BB rats. II. Impaired bone turnover and decreased osteocalcin synthesis. Endocrinology 1989, 124:573-582.
110. Lipscombe L.L., Jamal S.A., Booth G.L., Hawker G.A. The risk of hip fractures in older individuals with diabetes: a population-based study. Diabetes Care 2007, 30:835-841.
111. Kanazawa I., Yamaguchi T., Yamamoto M., Yamauchi M., Yano S., Sugimoto T. Combination of obesity with hyperglycemia is a risk factor for the presence of vertebral fractures in type 2 diabetic men. Calcif Tissue Int 2008, 83:324-331.
112. Minn A.H., Patterson N.B., Pack S., Hoffmann S.C., Gavrilova O., Vinson C., et al. Resistin is expressed in pancreatic islets. Biochem Biophys Res Commun 2003, 310:641-645.
113. Wang W., Zhang X., Zheng J., Yang J. High glucose stimulates adipogenic and inhibits osteogenic differentiation in MG-63 cells through cAMP/protein kinase A/extracellular signal-regulated kinase pathway. Mol Cell Biochem 2010, 338:115-122.
114. Price P.A., Roublick A.M., Williamson M.K. Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate. Kidney Int 2006, 70:1577-1583.
115. Pennisi P., Signorelli S.S., Riccobene S., Celotta G., Di Pino L., La Malfa T., et al. Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. Osteoporos Int 2004, 15:389-395.
116. Parker B.D., Bauer D.C., Ensrud K.E., Ix J.H. Association of osteocalcin and abdominal aortic calcification in older women: the study of osteoporotic fractures. Calcif Tissue Int 2010, 86:185-191.
117. Verma S., Li S.H., Wang C.H., Fedak P.W., Li R.K., Weisel R.D., et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003, 108:736-740.
118. Calabro P., Samudio I., Willerson J.T., Yeh E.T. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation 2004, 110:3335-3340.
119. Burnett M.S., Lee C.W., Kinnaird T.D., Stabile E., Durrani S., Dullum M.K., et al. The potential role of resistin in atherogenesis. Atherosclerosis 2005, 182:241-248.
120. Calabro P., Cirillo P., Limongelli G., Maddaloni V., Riegler L., Palmieri R., et al. Tissue factor is induced by resistin in human coronary artery endothelial cells by the NF-kB-dependent pathway. J Vasc Res 2011, 48:59-66.
121. Dullaart R.P., de Vries R., van Tol A., Sluiter W.J. Lower plasma adiponectin is a marker of increased intima-media thickness associated with type 2 diabetes mellitus and with male gender. Eur J Endocrinol 2007, 156:387-394.
122. Jeon M.J., Kim J.A., Kwon S.H., Kim S.W., Park K.S., Park S.W., et al. Activation of peroxisome proliferator-activated receptor-gamma inhibits the Runx2-mediated transcription of osteocalcin in osteoblasts. J Biol Chem 2003, 278:23270-23277.
123. Barac A., Campia U., Matuskey L.A., Lu L., Panza J.A. Effects of peroxisome proliferator-activated receptor-gamma activation with pioglitazone on plasma adipokines in nondiabetic patients with either hypercholesterolemia or hypertension. Am J Cardiol 2008, 101:980-985.
124. Schwartz A.V., Sellmeyer D.E. Effect of thiazolidinediones on skeletal health in women with Type 2 diabetes. Expert Opin Drug Saf 2008, 7:69-78.
125. Solomon D.H., Cadarette S.M., Choudhry N.K., Canning C., Levin R., Sturmer T. A cohort study of thiazolidinediones and fractures in older adults with diabetes. J Clin Endocrinol Metab 2009, 94:2792-2798.
126. Banerjee R.R., Lazar M.A. Resistin: molecular history and prognosis. J Mol Med 2003, 81:218-226.
127. Barnes K.M., Miner J.L. Role of resistin in insulin sensitivity in rodents and humans. Curr Protein Pept Sci 2009, 10:96-107.
128. Stan D., Calin M., Manduteanu I., Pirvulescu M., Gan A.M., Butoi E.D., et al. High glucose induces enhanced expression of resistin in human U937 monocyte-like cell line by MAPK- and NF-kB-dependent mechanisms; the modulating effect of insulin. Cell Tissue Res 2010.
129. Silswal N., Singh A.K., Aruna B., Mukhopadhyay S., Ghosh S., Ehtesham N.Z. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem Biophys Res Commun 2005, 334:1092-1101.
130. Kralisch S., Sommer G., Stangl V., Kohler U., Kratzsch J., Stepan H., et al. Secretory products from human adipocytes impair endothelial function via nuclear factor kappaB. Atherosclerosis 2008, 196:523-531.
131. Schaffler A, Buchler C, Muller-Ladner U, Herfarth H, Ehling A, Paul G, et al. Identification of variables influencing resistin serum levels in patients with type 1 and type 2 diabetes mellitus 2004;36:702-7.